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ReviewGlossary
Lipoxin A4 (LXA4):
15-Epi-LXA4: an aspirin-triggered lipoxin
Annexin Ac2–26: N-terminal domain of annexin A1, representing the bioactive
peptide spanning amino acids 2–26.
Complement 5a (C5a) receptor (C5AR): also known as complement component
5a receptor 1 and CD88 (cluster of differentiation 88); a G-protein-coupled
receptor for C5a.
Dissociation constant (Kd): measure of how tightly a ligand binds to a
particular receptor. Low ligand Kd values reflect a high affinity for the receptor.
G-protein-coupled receptors (GPCRs): proteins with an extracellular domain
and an intracellular C-terminal tail, separated by three extracellular loops and
three intracellular loops. They are the largest family of membrane receptors
and couple to intracellular effector systems via a G protein.
Intravital microscopy (IVM): real-time qualitative and quantitative method for
observing cell–cell interactions in the microcirculation of an anaesthetized
animal.Ischaemia–reperfusion (I/R) injury is a common feature
of several diseases associated with high morbidity and
mortality, such as stroke and myocardial infarction. The
damaged tissue displays cardinal signs of inflammation
and microvascular injury that, unless resolved, lead to
long-term tissue damage with associated dysfunction.
Current therapies are limited and are often associated
with many side effects. Increasing evidence suggests
that members of the formyl peptide receptor (FPR)
family, in particular human FPR2/ALX, might have an
important role in the pathophysiology of I/R injury. It
was recently demonstrated that several peptides and
non-peptidyl small-molecule compounds have anti-
inflammatory and pro-resolving properties via their
action on members of the FPR family. Here I review this
evidence and suggest that FPR ligands, particularly in
the brain, could be novel and exciting anti-inflammatory
therapeutics for the treatment of a variety of clinical
conditions, including stroke.
Introduction
Ischaemia–reperfusion (I/R) contributes to the pathophy-
siology of many clinical problems such as myocardial
infarction, stroke, resuscitation, coronary bypass surgery,
frostbite, extension of burn injury and organ transplan-
tation. According to the American Heart Association, more
than 1 million people suffer a heart attack each year and
approximately 795,000 suffer a stroke. These diseases
significantly contribute to the mortality rate and full
recovery is unlikely, with the single most important factor
being the degree of ischaemic damage at the time of the
event. Ischaemia refers to a reduction in blood flow and
reperfusion injury is associated with an initial blood-borne
neutrophil infiltration, giving rise to an inflammatory
response and finally resulting in tissue injury [1–3].
Although restoration of blood flow to a previously
ischaemic region is essential to prevent irreversible tissue
damage, reperfusion itself is a double-edged sword and
thus is not always beneficial. Although a great deal of
damage occurs to the tissue because of reperfusion, a
significant amount of injury occurs due to ischaemia itself.
During myocardial injury, several events occur that med-
iate vascular injury, including oxygen free radical pro-
duction by mitochondrial respiration, activated
neutrophils and xanthine oxidase activity [3]. These areCorresponding author: Gavins, F.N.E. (f.gavins@imperial.ac.uk).
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selves activating leukocytes, inducing lipid peroxidation
and increasing vascular permeability.
Leukocyte recruitment occurs in the microvasculature
and involves a complex set of events that can occur both
locally and systemically. Both in vivo and in vitro evidence
(e.g. antibodies against adhesion molecules; chemotaxis
and transmigration assays; flow chamber assays; and
real-time studies to visualise cellular interactions in the
circulation of anaesthetised animals using intravital
microscopy) have demonstrated molecular and cellular
pathways involved in this multi-step cascade. The leuko-
cyte adhesion cascade involves: capture, rolling, slow roll-
ing, leukocyte arrest, post-adhesion strengthening,
intravascular crawling and paracellular or transcellular
transmigration [4] (Figure 1).Neutrophil: white blood cell.
ed. doi:10.1016/j.tips.2010.04.001 Trends in Pharmacological Sciences 31 (2010) 266–276
Figure 1. Example of an inflamed murine mesenteric venule. This picture
demonstrates the steps involved in the inflammatory cascade: leukocyte capture,
rolling, slow rolling, arrest, post-adhesion strengthening, intravascular crawling
and either paracellular or ranscellular migration of leukocytes into the surrounding
tissue.
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ent pathogens and noxious stimuli that enter the system.
Injury to the body provokes a host acute inflammatory
response of pain, fever, redness, swelling and, in the case of
chronic inflammation, loss of function. The inflammatory
response is characterised by leukocyte infiltration, which is
achieved by integrins, adhesion, selectins and glycoprotein
selectin ligands in response to cytokines and chemotactic
factor gradients. These factors mediate the inflammatory
cascade, involving leukocyte rolling, adhesion and trans-
endothelial migration [3,4] (Figure 1). Numerous receptors
modulate the host inflammatory response. Under abnor-
mal situations, the body’s response can assume the char-
acter of a disease itself [5], resulting in tissue damage, as
observed in pathological conditions such as I/R injury.
Microvascular dysfunctions are observed on reperfusion
of ischaemic tissue, including endothelial-dependent
dilation of arterioles and increased fluid filtration andBox 1. FPR signalling and nomenclature
FPR signalling
Leukocyte responses to chemoattractants, such as fMLP, require
binding and activation of pertussin-toxin-sensitive GPCR coupling
to Gia2 or Gia3, which triggers multiple second messengers through
phospholipase C (PLC), PLD and PLA2 activation [8]. fMLP stimula-
tion of leukocytes induces shape changes, chemotaxis, adhesion,
phagocytosis and the release of superoxide anions and granule
contents, leading to tissue damage, as observed in inflammation
and infarction [86]. All major neutrophil functions stimulated by
fMLF can be inhibited by treatment of the cells with pertussis toxin,
indicating that the FPRs belong to the Gi family of heterotrimeric G
proteins [11].
All three human FPRs are clustered on chromosomal region
19q13.3 [11], whereas the murine equivalents are arranged in two
clusters on chromosome 17 (A3.2) together with an additional
pseudogene (CFpr2) [18] based not on receptor structure, but on
receptor agonists (Table 2).
FPR nomenclature
Human: Table 1 demonstrates human FPR nomenclature [11,19].
FPR2/ALX shares 69% sequence homology with FPR1. Both FPR2/ALX
and FPR3 possess high degrees of amino acid identity (69%) [15,20],leukocyte plugging in capillaries, leading to a no-reflow
phenomenon [3]. On the basis of current understanding of
I/R, several potential treatments have been suggested
based onmechanical (e.g. coronary angioplasty or stenting)
or pharmacological (e.g. anti-platelet therapy, tissue plas-
minogen activator administration, neutralization of
already secreted pro-inflammatory cytokines, adminis-
tration of anti-inflammatory cytokines, factors favouring
mesenchymal stem cell implantation and mobilization)
restoration of blood flow [2,6,7]. Other therapeutic
approaches have been explored such as targeting of recep-
tors implicated in regulating and resolving the inflam-
mation associated with I/R. One such family of receptors
is the G-protein-coupled receptors (GPCRs) known as the
formyl peptide receptors (FPRs), whose involvement in I/R
injury has been demonstrated in a variety of different
tissues, and thus ligands for FPRs might play a role in
host defense.
The FPRs are promiscuous in their ability to bind
different ligands, such as formyl-Met-Leu-Phe (fMLP)
and lipoxin A4 (LXA4) (Box 1, Table 2). However, the
receptors are expressed in different cells and tissues,
raising the possibility that FPRs have far more diverse
and complex roles in biology. Interestingly, resolution of
inflammation involves the formation of endogenous anti-
inflammatory mediators, which signals the termination of
recruitment and removal of inflammatory cells from the
inflammatory locus [8]. In this review, I summarise the
evidence for proposing FPR ligands as novel anti-inflam-
matory and pro-resolving therapeutics and focus on their
role in reducing the detrimental effects associated with I/R
injury.
The FPR family: tissue and cellular distribution
FPR1 is one of the best-studied GPCRs, dating back to the
early 1970s [9], and its activation produces a range of
inflammatory responses associated with I/R, such as
stimulation of leukocyte migration [8]. FPR1 has been
found in a variety of different tissues and cells (Table 2)but are activated by different ligands (Table 2). The FPR3 gene
encodes a putative protein with 56% amino acid similarity to FPR1
and 72% to FPR2/ALX.
Non-human: A high degree of specificity to human orthologue
genes occurs in non-human primates (95–99%) [11]. The situation is
complicated in mice, with gene clusters having undergone differential
expansion. The mouse genome encodes for at least seven different
receptors (Table 1). It is now agreed that murine Fpr1 is 77% identical
to human FPR1 [11] and Fpr3 is 76% identical to human FPRL2. Fpr2
binds fMLF with low affinity [11,18]. Fpr-r3, 4, 6 and 7 seem to have no
direct counterparts in the human genome [73]. Fpr-rs4 encodes a
receptor with a short COOH-terminal domain, whereas Fpr-rs5 has a
stop codon in the putative transmembrane domain 6 (more likely to
be a pseudogene) [73]. Two additional genes were characterised from
screening of a mouse BAC genomic library, termed Fpr-rs6 and Fpr-
rs7 [105]. Other orthologues have been found at a molecular level in
species such as rabbit and primates and at a functional level in rat
[106], guinea pig and horse (as reviewed in [11]).
It is noteworthy that there is chemoattractant receptor-like molecule
(CRTH2) from a human Th2 clone that has high amino-acid homology
with members of the FPR family. However, the similarity is
insufficient to classify CRTH2 as an FPR member.
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Table 1. Tissue distribution and IUPHAR nomenclature for human and murine FPRs
Species Previous nomenclature IUPHAR
nomenclature




FPR1 Adrenal glands, adrenal cortical cells, astrocytes, bone marrow, carcinoma cells,
CNS, colon, endothelial cells, epithelial cells, eye, fibroblasts, heart, hepatocytes,
immature DCs, kidney, Kupffer cells, liver, lung, macrophages, microglial cells,








FPR2/ALX Astrocytes, bone marrow, brain, endothelial cells, epithelial cells, fibroblasts,
hepatocytes, immature DCs, lung, macrophages, microglial cells, monocytes,






FPR3 Adrenal gland, DCs, HL-60 cells, liver, lung, lymph nodes, macrophages,
monocytes, placenta, small intestine, spleen, trachea
Mouse Fpr1 Fpr1 Adrenal gland, anterior pituitary, DCs, hippocampus, hypothalamus, liver,
lung, microglia, mononuclear cells, neutrophils, spleen




Fpr3 Adrenal gland, anterior pituitary, heart, hippocampus, hypothalamus, liver, lung,
microglia, neutrophils, spleen
Fpr-rs3 Fpr-rs3 Skeletal muscle
Fpr-rs4 Fpr-rs4 ?
Fpr-rs5 Fpr-rs5 ?
Fpr-rs6 Fpr-rs6 Brain, skeletal muscle, spleen, testis
Fpr-rs7 Fpr-rs7 Heart, liver, lung, pancreas, smooth muscle, spleen
Fpr-rs8 Fpr-rs8 ?
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lets and dendritic cells (DCs) [10] (possibly important for
modulation of T-cell activation) [11]. FPR2/ALX is equally
widely distributed, with an interesting presence, in
addition to peripheral cells and tissues, in brain and spinal
cord, and is functionally expressed in glial cells, fibroblasts
and astrocytes [12–15].
Functional FPRs are widely expressed in non-lymphoid
tissues, including normal human lung and skin fibroblasts
and the human fibrosarcoma cell line HT-1080. Van Com-
pernolle demonstrated that fibroblasts express FPRs that
respond in a chemoattractant manner on treatment with
fMLP [15], thus opening up a new area for a role of non-
leukocyte cell types in innate immune responses (recently
reviewed in [11]). FPR3 seems to be present not in neu-
trophils, but in monocytes [11]. Fascinatingly, this tissue
distribution varies with the monocyte differentiation stage
[10,11], with mature DCs mainly expressing FPR3 [11].
Cui et al. [14] used primary microglia cells to demon-
strate expression of FPR1 and FPR2/ALX genes; on stimu-
lation with bacterial lipopolysaccharide (LPS), these cells
undergo FPR2/ALX-mediated activation, leading to the
suggestion that the blood brain barrier (BBB), under nor-
mal conditions, protects microglial cells. When endotoxae-
mia occurs, however, microvessels form an incomplete
BBB and LPS is able to stimulate microglial cells, which
assume macrophage characteristics and thus play a role in
the inflammatory process [16]. Increased inflammatory
events, such as leukocyte rolling and adhesion, occur in
the murine cerebral microcirculation after endotoxaemia
(something not observed under normal conditions) and
seem to be mediated by FPR2/ALX (Gavins et al., unpub-
lished observations). The increase in inflammatory events268such as leukocyte rolling and adhesion observed following
endotoxaemia also occurs during stroke. The role of FPR2/
ALX in stroke is of great interest to my research team and
the importance of this receptor as a potential therapeutic
target is currently being investigated. The role of the FPRs
in cerebral I/R is discussed in more detail later in this
review.
A variety of different agonists and antagonists are
currently availbale for the FPR family (Table 2). It is
not possible to cover all of them within this review, so I
have focussed on the more widely used ones.
FPR pharmacology
Agonists
The emergence of more sensitive techniques, such as com-
puter-assisted 3D modelling, has helped us to understand
how ligands bind to different receptors. Several natural
formylated peptides have been purified from bacterial
supernatants and exhibit the ability to activate human
leukocytes [17]. fMLP is a widely used agonist of the FPR
family and binds to FPR1 with approximately 1000-fold
higher affinity than FPR2/ALX (Kd values in the picomolar
to low nanomolar range), resulting in calciummobilization
and neutrophil activation [18]. Evidence suggests that
FPR1 and FPR2/ALX activate the same signal response
downstream of the receptor, resulting from activation
produced by different ligands [11,19]. FPR2/ALX is a
low-affinity receptor for fMLP (Kd 430 nM) [11,20] that
produces a chemotactic response at micromolar concen-
trations. (FPR3 has a Kd value of 10 mM [21]). LXA4 also
interacts with FPR2/ALX (Kd 0.5 nM) [22,23], inhibiting
the pro-inflammatory responses induced by both FPR2/
ALX ligands in neutrophils and non-FPR2/ALX ligands in
Table 2. Non-exhaustive list of agonists and antagonists of human and murine FPRs and examples of specific effectsa
Receptor Agonist or Ligand Example of a specific effect Refs
antagonist
FPR1 Agonists Ac2–12 Cardio-protective in murine model of myocardial infarction [53]
Ac9–25 Activates neutrophil release of O2
 [76]
Ac2–26 Decreases neutrophil–endothelium interactions in flow chamber [77]
Annexin 1 Decreases neutrophil–endothelium interactions in flow chamber [77]
Cathepsin G Chemoattractant for phagocytic leukocytes [78]
fMLP and analogues Defective PMN chemotaxis in juvenile peridontitis in vivo [79]
Chemotaxis, lysozyme release, O2
 production, including
endothelial interaction, all in neutrophils
HIV-1 T20 (DP178) Chemoattractant and activator of peripheral phagocytes [47,48]
HIV-1 T21 (DP107) Chemoattractant and activator of peripheral phagocytes (low affinity) [47]
HIV gp41 Induces directional migration and calcium mobilization in
human monocytes and neutrophils
[49]
HSV gG-2p20 Chemoattractant for monocytes and neutrophils [50]
LL-37 Chemoattractant for human peripheral blood neutrophils,
monocytes and T cells
[23]
SRSRY Directional cell migration on vitronectin-coated filters [80]
WKYMVM Activates neutrophils (low affinity) [28]
WKYMVm peptide Activates neutrophils (low affinity) [28]
FPR1 Antagonists CDCA Inhibits neutrophil chemoattraction and migration (high affinity) [58]
CHIPS Inhibits chemotaxis in S. aureus infection (low affinity) [55]
Coronavirus
229E peptides
Ligand binding studies using transfected CHO cells
demonstrated antagonsism of FPR2
[81]
Coronavirus peptides Inhibits fMLP interaction in CHO cells [81]
Cyclosporine A Inhibits fMLF-stimulated degranulation, chemotaxis,
calcium mobilization of neutrophils
[82]
Cyclosporine H Decreased neutrophil activation (high affinity) [83]
DCA Inhibits fMLP-induced monocyte and neutrophil chemotaxis
and calcium mobilization
[57]
Ebola peptides Inhibits fMLP interaction in CHO cells [81]
FLIPr FPRL1 inhibitory protein (FLIPr) inhibits leukocyte responses
to FPR2 agonists
[56]
HIV-2 peptides Inhibits fMLP interaction in CHO cells [81]
Isopropylureido-FLFLF Inhibits chemotaxis [84]
Spinorphin Inhibits calcium mobilization in mouse-FPR transfected human
embryonic kidney cells
[85]
tBOC Decreased neutrophil activation (low affinity) [83]
FPR2/ALX Agonists Ab42 Chemotaxis of mononuclear cells [86]
Annexin 1 Decreased neutrophil–endothelium interactions (firm adhesion)
in flow chamber
[77]
Antiflammin 2 Decreased neutrophil–endothelium interactions [87]
CRAMP Chemoattractant for leukocytes [88]
D2D388–274 Inhibits monocyte chemotaxis and integrin-dependent cell adhesion [89]
F peptide Downregulates expression and function of CCR5 and CXCR4
in monocytes
[50]
fMLP and analogues Induces chemotaxis, lysozyme release, O2
 production in neutrophils [11]
Formylated humanin Chemotaxis of human FPR2-transfected CHO cells [90]
HIV-1 T21 (DP107) Chemoattractant and activator of peripheral phagocytes (low affinity) [86]
Humanin Chemotaxis of human FPR2-transfected CHO cells [90]
Lipoxin A4 Attenuated hind limb I/R-induced lung injury [69]
LL37 Chemoattractant for monocytes, neutrophils and T cells [23]
MMK-1 Chemotaxis and calcium mobilization in monocytes and neutrophils [31]
N36 peptide Chemotaxis and calcium mobilization in monocytes and neutrophils [49]
NADH dehydrogenase Chemotaxis and calcium mobilization in human FPR2-expressing
HL-60 cells
[91]
PACAP27 Neutrophil chemotaxis and upregulation of CD11b [92]
PRP106-126 Endocytosis in glial cells [93]
Quin-C1 Chemotaxis and secretion of b-glucuronidase in peripheral neutrophils [94]
Rana-6 Chemoattractant of phagocytes [57]
Serum amyloid
A (SAA)
Chemoattractant for neutrophils [41]
T20 (DP178) Chemoattractant and activator of peripheral phagocytes [47,48]
T21 (DP107) Chemoattractant and activator of peripheral phagocytes (high affinity) [47]
Temporin A Chemoattractant of phagocytes [95]
uPAR84–95 Basophil chemotaxis [96]
V3 peptide Inhibits monocytic response to chemokines [97]
WKYMVM Activates neutrophils (high affinity); O2
 production [32]
WKYMVm peptide Activates neutrophils (high affinity) [98]
sCKb8-1 Alters protein pattern of PMN cells [99]
Hp2–20 Migration and proliferation of gastric epithelial cell lines MKN-28 and AGS [96]
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Table 2 (Continued )
Receptor Agonist or Ligand Example of a specific effect Refs
antagonist
Ac2–26 Decreased neutrophil–endothelium interactions (firm adhesion) in
flow chamber
[77]
Ac2–12 Cardioprotective in a murine model of myocardial infarction [53]
FPR2/ALX Antagonists CDCA Inhibits neutrophil chemoattraction and migration (low affinity) [95]
Coronavirus
229E peptides
Inhibits neutrophil chemoattraction and migration [58]
FLIPr Inhibits calcium mobilization [56]
Isopropylureido-FLFLF Inhibits chemotaxis [84]
PBP10 Inhibits granule mobilization and oxygen radical secretion [100]
tBOC Decreased neutrophil activation (high affinity) [83]
WRWWWW Inhibits oxidative burst from neutrophils, measured as a release
of superoxide anions
[100]
FPR3 Agonists Formylated peptides Triggers dose-dependent migration of fibroblasts in vitro [15]
WKYMVM Activates neutrophils [32]
WKYMVm peptide Activates neutrophils [98]
Annexin 1 Initiates chemotactic responses in human monocytes [39]
Hp(2–20) Chemoattractant for basophils [101]
Humanin Induces chemotaxis of mononuclear phagocytes in vitro [102]
F2L Promotes calcium mobilization and chemotaxis of monocytes and
monocyte-derived DCs
[103]
FPR3 Antagonists ETYIKPWWWVWL Inhibits fMLP interaction in CHO cells [81]
(from coronavirus 229E)
WRWWWW Inhibits calcium flux [32]
Fpr1 Agonists Ac2–26 Protect against experimental myocardial I/R [53]
Annexin 1 Protect against experimental myocardial I/R [53]
fMLP and analogues Chemoattractant for leukocytes [51]
T20 (DP178) Induced chemotaxis in primary PMNs and transfected cells in vitro [48]
WKYMVm Induced chemotaxis of transfected cells in vitro [99]
Fpr1 Antagonists Isopropylureido-FLFLF Inhibits chemotaxis [84]
Spinorphin Inhibits chemotaxis [84]
tBOC Prevents the protective effect of AnxA1 peptides in murine mesenteric
I/R preparations in vivo
[36]
Fpr2 Agonists Ab42 Induced chemotaxis of transfected cells in vitro [102]
Ac2–26 Decreases adhesion and emigration in inflamed mesentery in vivo [36]
Annexin 1 Cerebroprotective in a murine stroke model in vivo [54]
CRAMP Chemoattractant for leukocytes [88]
F2L Induced chemotaxis in transfected cells and primary PMNs in vitro [74]
fMLP and analogues Chemoattractant for neutrophils [105]
Humanin Induces chemotaxis of mononuclear phagocytes in vitro [102]
MMK-1 Induced chemotaxis of PMNs into air pouch in vivo [20]
SAA Induced chemotaxis of primary PMNs in vitro [85]
T20 (DP178) Induced chemotaxis in transfected cells but not primary PMNs in vitro [48]
V3 peptide Chemoattractant [14]
WKYMVm Potent stimulant for murine neutrophils [51]
Fpr2 Antagonists Isopropylureido-FLFLF Inhibits chemotaxis [84]
tBOC Decreased neutrophil activation (high affinity) [83]
Aspirin-triggered
lipoxins
Inhibited migration of PMNs into inflamed air pouch in vivo [20]
Fpr3
aCHIPS, chemotaxis inhibitory protein of S. aureus; CHO, Chinese hamster ovary; Hp(2–20), H. pylori peptide Hp(2–20); N36, synthetic peptide derived from HIV-1; PMN,
polymorphonucleocyte; spinorphin, LVVYPWT; V3, synthetic peptide derived from HIV-1.
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strate high affinity for the receptor.
To characterise further FPR interactions in phagocytes
and subsequent cellular activation, several fMLP-OMe
analogues have been synthesized [26] including for-Met-
Leu-Cys(OMe)-Cys-Leu-Met-fpr, which binds to FPR1 [27].
Recently, fMLP-OMe analogues with receptor affinity
greater than that of the parent fMLP-OMe have been
synthesized, creating the potential for use as carriers for
drugs [11].
Construction and screening of random peptide libraries
have become useful tools in developing biologically active
agents such as WKYMVm, which stimulates human B
lymphocyte and monocytic cell lines and neutrophils270[28,29] through both FPR1 and FPR2/ALX. In 1998, Klein
isolated many small peptide sequences that react with
FPR1 and FPR2/ALX [30], such as MMK-1
(LESIFRSLLFRVM), a potent FPR2/ALX-specific agonist
[31]. Other synthetic peptides such as His-Phe-Tyr-Leu-
Pro-Met-NH2 (HFYLPM) stimulate both monocytes and
neutrophils via FPR2/ALX binding [32]. The peptide frag-
ment of NADH dehydrogenase subunit 1 (MYFINILTL) is
an agonist specific for FPR2/ALX. Other recent screening
studies include a 152 GPCR screen that identified a novel
21-amino-acid peptide agonist of FPR2/ALX and FPR3
termed CGEN-855A (TIPMFVPESTSKLQKFTSWFM-
amide) [33] and a screen for unique non-peptide agonists
of FPR1/FPR2/ALX [33]. These screens demonstrate that
Review Trends in Pharmacological Sciences Vol.31 No.6agonists of FPR1/FPR-ALX have wide chemical diversity
and analysis of these and future agonists will enhance our
knowledge of ligand–FPR interactions [34].
Both exogenous and endogenous ligands interact with
the FPR family. One particular endogenous ligand that has
been widely studied is the glucocorticoid-regulated protein
annexin A1 (AnxA1), which counteracts leukocyte extra-
vasation (Figure 1) [35–37]. Using calcium binding assays
and L-selectin shedding protocols, Walther et al. demon-
strated that AnxA1 N-terminal-derived peptides act on
human neutrophils through FPR1 [38]. It was then shown
that AnxA1 peptides initiate chemotactic responses in
human monocytes, desensitizing cells to subsequent
stimulations [39].
Other endogenous ligands with physiological relevance
because of their involvement in pathological conditions are
the acute-phase protein serum amyloid A (SAA) [40,41],
and Ab42 [14,42] and PrP106–126 (a prion protein frag-
ment) [43], found in prion disease, all of which are required
in high micromolar concentrations to activate FPR2/ALX.
Serum SAA concentrations increase during acute-phase
responses, causing tissue and organ amyloidosis in chronic
inflammation [44,45] by inducing chemotaxis of phagocytic
leukocytes through FPR2/ALX [40,41]. It is thought that
pathophysiological concentrations of SAA activate FPR2/
ALX and could therefore be used as biomarker for inflam-
matory disease [46,47].
Ab42 is an enzymatic cleavage fragment of the amyloid
precursor protein (APP). Its aggregated form is the major
component of senile plaques, found in brain tissue of
patients with Alzheimer’s disease (AD). Ab42 has been
implicated in neurodegeneration and pro-inflammatory
responses observed in AD; it activates FPR2/ALX,
suggesting that FPR2/ALX might represent a potential
therapeutic target for AD treatment [14,42]. PrP106–126
stimulation of FPR2ALX on human monocytes caused
internalization of the receptor and a release of pro-inflam-
matory mediators [43].
Other potential ligands, including HIV-envelope
proteins gp41 (T20/DP178, T21/DP107 and N36) and
gp120 (F and V3 peptides), interact with FPR1 and/or
FPR2/ALX. T20/DP178 interacts with FPR1 in vitro [47]
and mouse Fpr1 in vivo [48]; T21/DP107 uses both FPR1
and FPR2/ALX (higher efficacy FPR2/ALX) [47] and N36
(overlaps with T21/DP107) signals through FPR2/ALX
[49]. In terms of the gp120-derived peptides, both F peptide
(20 amino acids) and V3 peptide (33 amino acids) interact
with FPR2/ALX [50]. The Helicobacter pylori peptide
Hp(2–20) also acts via FPR2/ALX, inducing NADPH
oxidase activation in human neutrophils [51].
It is clear from the above that a large amount of research
(still ongoing) has been performed to design a successful
ligand for the FPR family. A key aspect for this process
relies on target specificity, namely a ligand with high
affinity for FPR2/ALX and almost no affinity for FPR1.
Ligand target specificity can also reduce the risk of harmful
side effects produced by, for example, non-specific binding.
Antagonists
There are various antagonists, such as those formed by
replacing the N-formyl group of fMLP with t-butyloxycar-bonyl (tBOC) or isopropyl ureido, yielding peptides that
block fMLP interaction with its receptor [14,52]. Several
studies have used these Boc derivatives (that are non-
selective antagonists to all FPR family members) to
demonstrate FPR family involvement in diseases such
as myocardial infarction and stroke [53,54].
More selective antagonists are available, such as the
chemotaxis inhibitory protein (C5aR) of Staphylococcus
aureus (CHIPS), which is present in over 50% of clinical
strains of S. aureus and antagonises FPR2/ALX and the
complement component 5a receptor 1. More specifically, a
peptide fragment of CHIPS (FTFEPFPTNEEIESN) is se-
lective for FPR2 and not C5aR [55]. Another protein of S.
aureus that exhibits selective binding of and activation by
MMK-1 is FPRL1 inhibitory protein (FLIPr), which binds
directly to FPR1 and FPR2, but not FPR3 [56].
The bile acids deoxycholic acid (DCA) and chenodeoxy-
cholic acid (CDCA) antagonise both FPR1 and FPR2/ALX
[57], possibly suppressing anti-bacterial responses in indi-
viduals with cholestasis [58]. DCA inhibits fMLP-induced
monocyte and neutrophil migration and calcium mobiliz-
ation though fMLP binding to its receptors, whereas CDCA
selectively inhibits monocyte chemotaxis and calcium flux
induced by fMLP and W peptide, suggesting a mechanism
for inhibition of inflammation and suppression of innate
immune response [57,58]. Quin-c7, a synthetic non-peptide
antagonist of FPR2/ALX, has been developed through
chemical modification of Quin-C7 (an FPR2/ALX agonist)
[59].
Although different ligands continue to be identified for
the FPRs, there is a clear need to develop more potent and
specific agonists and antagonists to offer a greater thera-
peutic potential devoid of major side effects.
Involvement of FPRs in I/R
Our understanding of the complexity and need for a bal-
ance between pro- and anti-inflammatory pathways to
retain a homeostatic environment [60–63] has given rise
to a great number of possible drug targets of the FPR
family. In particular, targets activated by endogenous
anti-inflammatory mediators could be used for drug dis-
covery for both I/R and other disease states because they
are likely to have fewer side effects and their application
would be similar to mechanisms that the body uses to
reject inflammation [60]. One particular endogenous
ligand of interest is the 37-kDa protein AnxA1, whose
involvement with the FPR family has been widely studied
and which affords protection in a number of I/R models.
Initially, cardioprotection by AnxA1 was observed in rat
myocardial I/R injury [64]. It was not until 2001, however,
that La et al. [53] investigated the mechanistic and mol-
ecular basis of AnxA1 action and demonstrated that the
pharmacophore responsible for cardioprotection lies
within amino acids 2–12, with correct alignment being
crucial [53]. A clinical applicationwas hypothesised on the
basis of cardioprotection being retained by the AnxA1 N-
terminal peptide Ac2–26 (also termed AnxA1Ac2–26) when
administered 60 min into reperfusion [53]. Boc2 adminis-
tration demonstrated for the first time that FPRs are
involved in the cardioprotective properties of AnxA1.
Histology demonstrated that neutrophil influx into the271
Table 3. Examples of agonists used in different I/R modelsa




hBLTR TG mice Hind-limb I/R-induced
second-organ lung injury
(3-h I+3-h R)
ATL analogue Yes ALX/FPR2 [67]
LXA4 ALX/FPR2 [67]
Male FVB mice Hind-limb I/R-induced
second-organ lung injury
(1-h I+1-h R)
ATL analogue ZK-994 Yes ALX/FPR2 [69]
ATL analogue ZK-142 Yes ALX/FPR2 [69]
ATLa No ALX/FPR2 [69]
NIH Swiss mice Ischaemic acute renal







(25-min I + 2-h R)
Human recombinant annexin 1 Yes FPR1 [60]
Annexin 1 peptide Ac2–26 Yes FPR1 [60]
Annexin 1 peptide Ac2–12 Yes FPR1 [60]
Annexin 1 peptide scrambled Ac2–12 No [60]
Annexin 1 peptide Ac2–6 No [60]





Annexin 1/5 No [7]
Denatured preparation of annexin 1 No [7]
Human recombinant annexin 1 Yes Unknown receptor [7]
Male C57bl/6 mice Myocardial I/R
(25-min I+1-h R)
Annexin 1 peptide Ac2–26 Yes FPR3 [65]
W peptide Yes ALX/FPR2, Fpr3 [65]
ATLa-ME Yes ALX/FPR2, Fpr3 [65]
Male Fpr1-null mice Myocardial I/R
(25-min I+1-h R)
Peptide Ac2–26 Yes Excluded
involvement of Fpr1
[65]
W peptide Yes Excluded
involvement of Fpr1
[65]
ATLa-ME Yes ALX/FPR2, Fpr3 [65]
Male albino mice Myocardial I/R
(25-min I+2-h R)





CGEN-855A Yes ALX/FPR2 [33]
Male C57bl/6 mice Mesenteric I/R
(30-min I+45-min R)
Annexin 1 peptide Ac2–26 Yes Fpr1 and Fpr3 [36]
Male Fpr1-null mice Annexin 1 peptide Ac2–26 Yes, 50% Fpr1 and Fpr3 [36]




Splanchnic artery I/R Annexin 1 peptide Ac2–26 Yes Fpr1 [104]
Male Fpr2-null mice Mesenteric I/R
(30-min I+45-min R)
None Yes Fpr2 [71]
aATL, aspirin-triggered lipoxin; ATLa, 15-epi-16-( p-fluoro)-phenoxy lipoxin A4; ATLa-ME, ATLa methyl ester; hBLTR, human leukotriene B4 receptor; ATL analogue, 15-epi-16-
( p-fluoro)-phenoxy-LXA4 [15(S)-16-( p-fluoro)-phenoxy-LXA4 methyl ester]; peptide Ac2–6, acetyl-AMVSE; peptide Ac2–12, acetyl-AMVSEFLKQAW; peptide scrambled Ac2–
12, acetyl-SVEQKMWALFA; peptide Ac2–26, acetyl-AMVSEFLKQAWIENEEQEYVVQTVK; W peptide, WKYMVm (Trp-Lys-Tyr-Met-Val-D-Met).
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in sham and naı̈ve animals.
Although rat models provided novel results, murine
models are particularly useful given our current knowl-
edge of the genome and the ease of genetic manipulation
(Table 3). The Fpr1-null mouse provided evidence that
FPR1 does not mediate the cardioprotection afforded by
peptide AnxA1Ac2–26 [65]. Neutrophil depletion studies did
not affect the extent of acute heart injury, but affected
protection afforded by peptide AnxA1Ac2–26. This study
provided evidence of the role of mouse Fpr2 and/or Fpr3
and circulating neutrophils in mediating AnxA1-induced
cardioprotection.
Since reports providing theoretical frameworks for con-
sidering ALX/FPR2 as a putative target for I/R injury were
published [65–68], a number of novel ligands have been
identified, such as the peptide and ALX/FPR2 agonist272CGEN-855A, which has cardioprotective effects in rat
and murine myocardial I/R, reducing both infarct size
(by 25% and 36%, respectively) and murine troponin I
levels [36]. Thus, CGEN-855A elicits cardioprotection
similar to the effect reported for other ALX/FPR2 agonists
such as AnxA1 [65]. This study provides further evidence of
a beneficial effect of the ALX/FPR2 pathway in inflam-
mation [36].
Other agonists of ALX/FPR2 exhibit protective effects in
I/R models, such as15-epi-16-(p-fluorophenoxy)-LXA4-
methyl ester [15-epi-16-(FPhO)-LXA4-Me], which is protec-
tive in renal I/R in part by modulating cytokine and
chemokine expression and neutrophil recruitment [66].
The first evidence of ALX/FPR2 activation by aspirin-trig-
gered lipoxins was provided by Chiang et al., who demon-
strated protection from second-organ reperfusion injury
[67].
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analogues ZK-994 and ZK-142 have exhibited inhibition
of neutrophil accumulation in murine hind-limb I/R-
induced second-organ lung injury [69].
Intravital microscopy (IVM) has been used in I/R studies
to assess the effect of FPR ligands (Figure 1). IVM is a real-
timequalitative andquantitativemethod for observing cell–
cell interactions in the microcirculation of an anaesthetized
animal [70]. Our own I/R studies in the mesentery (30 min
I+45 min R, followed by mesenteric visualization using
IVM) of C57BL/6 and Fpr1-null mice demonstrated that
more than one FPR family member mediates the effects of
peptide AnxA1Ac2–26, possibly including mouse Fpr2. These
effects are similar to those observed inLPS-induceddamage
of the mouse mesentery (Hughes et al., unpublished data).
The availability of genetically modified mice has facili-
tated characterisation and understanding of the FPR
family, but differences between species remains an issue.
However, very recent studies using Fpr2-null mice and
IVM have revealed a marked increase in inflammation, as
demonstrated by an increase in cell adhesion and emigra-Figure 2. Schematic of how the FPR agonist AnxA1 could reduce inflammation in the bra
injury. They roll, adhere and migrate into the tissue. AnxA1 is released from neutrophil c
paracrine fashion. Administration of AnxA1 (or the N-terminal peptide Ac2–26) causes t
are also activated by I/R injury and, like blood-borne cells, release a plethora of dam
leukotrienes. The involvement of AnxA1 in these processes might be similar to that
receptors that mediate this process in stroke remain unknown, although evidence suggtion following mesenteric I/R [71]. These Fpr2-null mice
also had an augmented response to carrageenan-induced
paw edema in comparison to their wild-type counterparts
[71]. These studies, along with studies in my own labora-
tory looking at the effects of stroke in Fpr2-null mice
(Gavins, unpublished data), further demonstrate that
FPR2/ALX is an anti-inflammatory receptor and serves
a function in the host defence response.
It is clear that I/R elicits an acute inflammatory
response that is characterised by inflammatory cell recruit-
ment, oxidative stress and the failure of the endothelial
barrier, and contributes to the pathogenesis of many dis-
eases. One area in which targeting of inflammatory mar-
kers has failed to yield successful therapeutic drug
candidates is stroke. Evidence of FPRs and their agonists
as possible novel therapeutic targets for the treatment of
cerebral I/R injury is now discussed.
FPRs in cerebral I/R
When cerebral blood flow is restored following ischaemia,
several cascades are initiated, leading to activation ofin following I/R injury and exert neuroprotection. Neutrophils are activated after I/R
ytosolic granules to the cell surface, where it interacts with FPRs in an autocrine or
he leukocyte detachment from endothelial cells. Resident cells, such as microglia,
aging mediators such as reactive oxygen species, cytokines (TNF-a, IL-1b) and
observed in the peripheral microvasculature, namely to promote resolution. The
ests that FPR/ALX plays a role.
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neurons) [72]. The actual contribution of resident cells
versus blood-borne cells has yet to be fully quantified
and might explain why clinical trials targeting one specific
aspect of the inflammatory cascade have failed. A neuro-
protective role for AnxA1, mediated via FPRs, has been
demonstrated in studies using a middle cerebral artery
occlusion model combined with IVM to quantify cerebral
cellular interactions following stroke [54]. Peptide
AnxA1Ac2–26 decreased infarct volume, leukocyte adhesion
and markers of inflammation. Microglia might, in part,
contribute to these inflammatory responses [54]. Both
blood cells andmicroglia express mouse Fpr2, which might
have mediated the effects of peptide AnxA1Ac2–26 in this
study. Further studies are being performed to validate this
theory, with current data suggesting that microglial cell
inhibition reduces brain inflammation post-I/R (Gavins
and Perretti, unpublished data). Figure 2 demonstrates
how AnxA1 could act in an autocrine and/or paracrine
fashion with the members of the FPR family to reduce
inflammation by (i) causing detachment of leukocytes
within the microvasculature and (ii) inhibiting the pro-
duction of cytotoxic proinflammatory mediators by acti-
vated microglial cells, both of which are thought to play a
role in cerebrovascular events such as stroke [54].
Whether the mechanisms that mediate inflammatory
responses in the brain are the same as those observed in
the periphery remains to be determined. It is likely that
similar endogenous pathways are available throughout the
host, the mechanism(s) of action of which is to inhibit
molecular and cellular responses to (I/R) injury, such as
for CGEN-855A and AnxA1 peptides. These bioactive pep-
tides and associated FPRs could represent potential thera-
peutic targets [33].
The neuroprotective peptide humanin is an agonist of
FPR2/ALX and an endogenous ligand of FPR3 [73].
Another endogenous ligand of FPR3 is a peptide isolated
from the human haem-binding protein termed F2L (Ac
MLGMIKNSLFFGSVETWPWQVLNH2). F2L has weak
activity for FPR2/ALX and is not active for FPR1 [74].
However, it is an agonist for FPR3, binding and activating
the receptor at concentrations in the low nanomolar range
[75].
Concluding remarks
This review has drawn together compelling evidence to
suggest that ligands to the FPRs could provide novel
anti-inflammatory and pro-resolving therapeutics that
reduce the damage associated with I/R injury. The prom-
iscuity of these receptors in binding different ligands,
coupled with their presence in different cells and tissue,
indicates a diverse role in multiple biological settings.
Improved understanding of these fundamental functions
would instruct therapeutic target identification and drug
development. Thus, further study of endogenous anti-
inflammatory agonists, such as AnxA1, and the lipoxins
could lead to the identification and development of better
therapeutics capable of limiting the detrimental effects
of I/R injury and promoting resolution, with fewer side
effects.274References
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